全文获取类型
收费全文 | 728557篇 |
免费 | 50481篇 |
国内免费 | 1344篇 |
专业分类
耳鼻咽喉 | 9433篇 |
儿科学 | 24096篇 |
妇产科学 | 18157篇 |
基础医学 | 113393篇 |
口腔科学 | 20603篇 |
临床医学 | 66437篇 |
内科学 | 138199篇 |
皮肤病学 | 16455篇 |
神经病学 | 51473篇 |
特种医学 | 26487篇 |
外国民族医学 | 77篇 |
外科学 | 108159篇 |
综合类 | 15280篇 |
现状与发展 | 2篇 |
一般理论 | 173篇 |
预防医学 | 53610篇 |
眼科学 | 16903篇 |
药学 | 55164篇 |
3篇 | |
中国医学 | 2365篇 |
肿瘤学 | 43913篇 |
出版年
2021年 | 5765篇 |
2019年 | 5773篇 |
2018年 | 8315篇 |
2017年 | 6432篇 |
2016年 | 7118篇 |
2015年 | 7912篇 |
2014年 | 10872篇 |
2013年 | 16226篇 |
2012年 | 21674篇 |
2011年 | 22742篇 |
2010年 | 13459篇 |
2009年 | 12553篇 |
2008年 | 21051篇 |
2007年 | 22686篇 |
2006年 | 23028篇 |
2005年 | 21622篇 |
2004年 | 21076篇 |
2003年 | 19958篇 |
2002年 | 19393篇 |
2001年 | 36809篇 |
2000年 | 37407篇 |
1999年 | 30829篇 |
1998年 | 8142篇 |
1997年 | 6859篇 |
1996年 | 7173篇 |
1995年 | 6810篇 |
1994年 | 6287篇 |
1992年 | 23398篇 |
1991年 | 23277篇 |
1990年 | 22640篇 |
1989年 | 22380篇 |
1988年 | 20349篇 |
1987年 | 19694篇 |
1986年 | 18753篇 |
1985年 | 17596篇 |
1984年 | 12930篇 |
1983年 | 10984篇 |
1982年 | 6102篇 |
1979年 | 11783篇 |
1978年 | 8327篇 |
1977年 | 6995篇 |
1976年 | 6746篇 |
1975年 | 7417篇 |
1974年 | 8685篇 |
1973年 | 8342篇 |
1972年 | 7809篇 |
1971年 | 7275篇 |
1970年 | 7006篇 |
1969年 | 6422篇 |
1968年 | 5867篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
M. Bergström G. Westerberg G. Németh M. Traut G. Gross G. Greger H. Müller-Peltzer A. Safer S.-Å. Eckernäs A. Grahnér B. Långström 《European journal of clinical pharmacology》1997,52(2):121-128
Objective: The aim of the study was to investigate whether or not esuprone binds substantially to MAO-A in the human brain. Methods: In a randomised double-blind placebo-controlled study 16 male healthy volunteers were examined␣with positron emission tomography
(PET) with [11C]harmine. Eight of the volunteers were given daily doses of 800 mg esuprone, four were given bi-daily doses of 300 mg moclobemide,
and four volunteers were given placebo tablets. PET was performed before initiation of a 7-day treatment period. On day 7,
one investigation was made immediately before administration of the drug, representing 23 h after the previous day's treatment
for esuprone and 11 h after the last tablets of moclobemide. Further investigations were made 4 h and 8 h after the morning
dose on day 7. Results: PET showed a high degree of binding of [11C]harmine, a high-affinity ligand for MAO-A, before the start of treatment, and a marked and similar reduction after treatment
with esuprone and moclobemide. A slight tendency for normalisation of enzyme binding was observed at the last time point.
In the placebo group no change was observed. Plasma kinetics of esuprone showed a rapid elimination with a half-life of about
4 h. Conclusion: The study demonstrates that esuprone was comparable to moclobemide in its effect on MAO-A inhibition in the brain at the
doses given. This is an illustration of the potential of PET to monitor drug effects directly on target biochemical systems
in the brain in human volunteers, and the possibility of using these data, rather than pharmacokinetic data, for the determination
of dosing intervals.
Received: 21 August 1996 / Accepted in revised form: 22 November 1996 相似文献
992.
993.
994.
Y. Kajiya M. Nakajo N. Ichinari Y. Kajiya K. Yamazumi T. Otuji T. Tanaka 《Abdominal imaging》1997,22(1):111-113
A foregut cyst is formed as a result of abnormal budding and pinching of the tracheobronchial tree when bronchial buds develop
to form the primitive respiratory tree. Foregut cysts are clinically classified as bronchogenic, esophageal, enterogastric,
or ciliated hepatic. We present a foregut cyst that occurred in the retroperitoneum and was difficult to distinguish from
other retroperitoneal cystic mass lesions. Magnetic resonance imaging was useful in revealing the cyst's continuity to adjacent
organs.
Received: 19 June 1995/Accepted: 23 July 1995 相似文献
995.
996.
997.
Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. 总被引:11,自引:0,他引:11 下载免费PDF全文
T Niwa T Katsuzaki S Miyazaki T Miyazaki Y Ishizaki F Hayase N Tatemichi Y Takei 《The Journal of clinical investigation》1997,99(6):1272-1280
To investigate the role of the Maillard reaction in the pathogenesis of diabetic complications, we produced several clones of monoclonal antibodies against advanced glycation end products (AGEs) by immunizing mice with AGE-modified keyhole limpet hemocyanin, and found that one clone (AG-1) of the anti-AGE antibodies reacted specifically with imidazolones A and B, novel AGEs. Thus, the imidazolones, which are the reaction products of the guanidino group of arginine with 3-deoxyglucosone (3-DG), a reactive intermediate of the Maillard reaction, were found to be common epitopes of AGE-modified proteins produced in vitro. We determined the erythrocyte levels of imidazolone in diabetic patients using ELISA with the monoclonal anti-imidazolone antibody. The imidazolone levels in the erythrocytes of diabetic patients were found to be significantly increased as compared with those of healthy subjects. Then we studied the localization of imidazolone in the kidneys and aortas obtained from diabetic patients by immunohistochemistry using the antibody. Specific imidazolone immunoreactivity was detected in nodular lesions and expanded mesangial matrix of glomeruli, and renal arteries in an advanced stage of diabetic nephropathy, as well as in atherosclerotic lesions of aortas. This study first demonstrates the localization of imidazolone in the characteristic lesions of diabetic nephropathy and atherosclerosis. These results, taken together with a recent demonstration of increased serum 3-DG levels in diabetes, strongly suggest that imidazolone produced by 3-DG may contribute to the progression of long-term diabetic complications such as nephropathy and atherosclerosis. 相似文献
998.
999.
1000.